Intravenous Ig (IVIg – polyclonal Ig) administration to neonates with Rhesus-mediated isoimmune haemolytic disease has been shown to decrease the need for exchange transfusion (number needed to treat=2.7).1 The use of IVIg as an adjuvant treatment for neonatal sepsis has been extensively studied. A 2010 Cochrane systematic review of this application in preterm (<37 weeks)/low birthweight (<2500 g) infants analysed the results of 19 studies involving 5000 infants. The authors concluded that IVIg administration resulted in a 3–4% reduction in sepsis or serious infection but was not associated with decreased …